Diagnosis of anorexia nervosa and bulimia nervosa using bdnf as a biological marker
CA 2500236 C · Owner: Koizumi, Hiroki · Inventors: Koizumi, Hiroki; Hashimoto, Kenji; Iyo, Masaomi
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention provides a diagnostic agent for eating disorders comprising as an active ingredient an antibody against brain-derived neurotrophic factor, and a method for detecting eating disorders comprising measuring of the concentration of a brain-derived neurotrophic factor in blood. Particularly, the eating disorders can easily be diagnosed by measuring the concentration of a brain-derived neurotrophic factor in blood of the patients with an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed September 24, 2003 and granted March 13, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended September 24, 2023.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by September 24, 2025.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.